Abcuro
Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease.
$66MSeries D
Role not disclosedFC
Foresite Capital
Activity from announced rounds
Activity in this selectionAug 31, 2026 · Aug 1, 2026
Foresite Capital is a healthcare investment firm identified by Abcuro and in its own Thyme Care portfolio record.
Recorded funding activity
Abcuro develops immunotherapies targeting pathogenic cytotoxic T cells. Thyme Care combines oncology care teams with technology, while Khartis develops oral medicines for immune and chronic diseases. The company histories distinguish care delivery from experimental drug development.
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $116M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionKhartis Therapeutics
Develops oral small molecule therapies for immunological and chronic diseases
$50MSeries B
Role not disclosed